You have 9 free searches left this month | to do more
Showing 1 - 25 of
>10,000 items
Trials Per Page
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
D
Copanlisib Plus Ibrutinib in R/R CLL
Recruiting
  • Chronic Lymphocytic Leukemia (CLL)
  • +2 more
  • Boston, Massachusetts
    Dana-Farber Cancer Institute
2021-09-08
Sep 8, 2021
V
Rituximab, Idelalisib, and Venetoclax in Relapsed/Refractory CLL/SLL - 2021
Withdrawn
  • Chronic Lymphocytic Leukemia
  • +8 more
  • Dose combination 1-1
  • +5 more
  • (no location specified)
2021-11-01
Nov 1, 2021
M
Rituximab Plus Venetoclax in Combination With Zandelisib in Subjects With CLL
Not yet recruiting
  • CLL
  • (no location specified)
2022-02-08
Feb 8, 2022
J
AU2 In Relapsed and Untreated CLL
Recruiting
  • Chronic Lymphocytic Leukemia
  • +3 more
  • Boston, Massachusetts
  • +2 more
2021-05-10
May 10, 2021
U
Phase II Trial of Revlimid® and Rituximab for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Active, not recruiting
Has Results
  • Chronic Lymphocytic Leukemia
  • CLL
  • La Jolla, California
    University of California, San Diego
2021-09-02
Sep 2, 2021
S
Venetoclax and Ibrutinib in Patients With Relapsed/Refractory CLL or SLL - 2021
Completed
Has Results
  • Recurrent Chronic Lymphocytic Leukemia
  • +3 more
  • Duarte, California
  • +1 more
2021-09-01
Sep 1, 2021
U
Rituximab + High-Dose Methylprednisolone Debulking Prior to Venetoclax for CLL & SLL Patients
Recruiting
  • Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
  • HDMP + rituximab as a means of debulking prior to initiating venetoclax.
  • La Jolla, California
    UCSD Moores Cancer Center
2022-03-21
Mar 21, 2022
D
The Safety of Repurposing Daratumumab for Relapsed or Refractory Autoimmune Antibody Mediated Hemolytic Anemia
Not yet recruiting
  • Hemolytic Anemia
  • Daratumumab / Hyaluronidase Injection
  • (no location specified)
2022-03-15
Mar 15, 2022
B
CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR)
Recruiting
  • Refractory B-Cell Non-Hodgkin Lymphoma
  • +4 more
  • CD19.CAR-aNKT cells
  • +2 more
  • Houston, Texas
  • +1 more
2021-08-12
Aug 12, 2021
M
Daratumumab and Ibrutinib for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia, DIRECT Study
Recruiting
  • Recurrent Chronic Lymphocytic Leukemia
  • +4 more
  • Jacksonville, Florida
    Mayo Clinic in Florida
2022-03-22
Mar 22, 2022
S
A Prospective, Multicenter, Phase-II Trial of Ibrutinib Plus Venetoclax in Patients With Creatinine Clearance >= 30 ml/Min Who Have Relapsed or Refractory Chronic Lymphocytic Leukemia (RR-CLL) With or Without TP53 Aberrations
Active, not recruiting
  • Chronic Lymphocytic Leukemia in Relapse
  • Chronic Lymphocytic Leukemia in Remission
  • Ibrutinib + Venetoclax 15 cycles
  • +2 more
  • Antwerpen, Belgium
  • +48 more
2022-03-16
Mar 16, 2022
S
A Study of XY0206 Tablets in Patients With Relapsed / Refractory Acute Myeloid Leukemia
Recruiting
  • Acute Myeloid Leukemia
  • Tianjin, Tianjin, China
    Institute of Hematology, Chinese Academy of Medical Sciences
2021-12-11
Dec 11, 2021
D
Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RS
Recruiting
  • Chronic Lymphocytic Leukemia
  • Richter Syndrome
  • Miami, Florida
  • +6 more
2021-11-22
Nov 22, 2021
A
Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL
Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • +2 more
  • Columbus, Ohio
    Research Site
2022-03-11
Mar 11, 2022
G
A Safety, Tolerability, Pharmacokinetics and Efficacy Study of GB261 in B-Cell NHL and CLL.
Recruiting
  • B Cell NHL
  • CLL
  • GB261
  • Melbourne, The State Of Victoria, Australia
  • +2 more
2022-04-01
Apr 1, 2022
U
Pitavastatin in Combination With Venetoclax for Chronic Lymphocytic Leukemia or Acute Myeloid Leukemia
Recruiting
  • Acute Myeloid Leukemia
  • +5 more
  • Orange, California
    Chao Family Comprehensive Cancer Center, University of Californi
2021-03-25
Mar 25, 2021
H
Dose Finding Study of Ibrutinib Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell Lymphoma
Active, not recruiting
  • Mantle Cell Lymphoma
  • Hackensack, New Jersey
    The Cancer Center at Hackensack University Medical Center
2021-04-30
Apr 30, 2021
M
Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL
Recruiting
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • Boston, Massachusetts
  • +2 more
2021-08-09
Aug 9, 2021
P
TAA6 Cell Injection In The Treatment of Patients With Relapsed / Refractory Acute Myeloid Leukemia
Recruiting
  • CAR
  • Acute Myeloid Leukemia
  • Chimeric antigen receptor T cells (car-t)
  • Hefei, Anhui, China
    Anhui Provincial Hospital
2021-03-04
Mar 4, 2021
S
A Phase Ib Study of CT053PTSA in Relapsed / Refractory Acute Myeloid Leukemia (AML) - 2019
Terminated
  • Acute Myeloid Leukemia (AML)
  • Tianjin, China
    Hospital of Blood Disease, Chinese Academy of Medical Sciences
2021-03-22
Mar 22, 2021
U
Venetoclax Resistance Landscape in Chronic Lymphocytic Leukemia
Recruiting
  • Chronic Lymphocytic Leukemia
  • +4 more
    • Bobigny, France
    • +8 more
    2022-03-23
    Mar 23, 2022
    C
    Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma
    Recruiting
    • B-Cell Prolymphocytic Leukemia
    • +17 more
    • Buffalo, New York
    • +1 more
    2021-07-04
    Jul 4, 2021
    A
    Calquence CLL rr Japan PMS_Japan Post-Marketing Surveillance (PMS) Study - All Patient Investigation
    Active, not recruiting
    • Relapsed or Refractory Chronic Lymphocytic Leukemia (Including Small Lymphocytic Lymphoma)
      • Aichi, Japan
      • +36 more
      2022-03-14
      Mar 14, 2022
      Z
      Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas
      Recruiting
      • Relapsed Chronic Lymphocytic Leukemia
      • +4 more
      • Phoenix, Arizona
      • +6 more
      2022-03-21
      Mar 21, 2022
      U
      Treatment of Relapsed or Refractory Neuroblastoma and Osteosarcoma With Expanded Haploidentical NK Cells and Hu14.18-IL2
      Suspended
      • Neuroblastoma
      • +3 more
      • Ex vivo Expanded and Activated Haploidentical Donor NK Cells
      • Hu14.18-IL2
      • Madison, Wisconsin
        University of Wisconsin Carbone Cancer Center; UW Hospital and C
      2021-08-04
      Aug 4, 2021